- Home
- GLU vs CUE Comparison
GLU vs CUE Comparison
Compare GLU & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLU
- CUE
- Stock Information
- Founded
- GLU 2004
- CUE 2014
- Country
- GLU United States
- CUE United States
- Employees
- GLU N/A
- CUE N/A
- Industry
- GLU Finance/Investors Services
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- GLU Finance
- CUE Health Care
- Exchange
- GLU Nasdaq
- CUE Nasdaq
- Market Cap
- GLU 92.2M
- CUE 94.4M
- IPO Year
- GLU N/A
- CUE 2018
- Fundamental
- Price
- GLU $16.05
- CUE $1.32
- Analyst Decision
- GLU
- CUE Strong Buy
- Analyst Count
- GLU 0
- CUE 5
- Target Price
- GLU N/A
- CUE $5.00
- AVG Volume (30 Days)
- GLU 12.4K
- CUE 195.8K
- Earning Date
- GLU 01-01-0001
- CUE 03-10-2025
- Dividend Yield
- GLU 8.60%
- CUE N/A
- EPS Growth
- GLU N/A
- CUE N/A
- EPS
- GLU 0.62
- CUE N/A
- Revenue
- GLU N/A
- CUE $9,532,000.00
- Revenue This Year
- GLU N/A
- CUE $73.11
- Revenue Next Year
- GLU N/A
- CUE $11.02
- P/E Ratio
- GLU $22.50
- CUE N/A
- Revenue Growth
- GLU N/A
- CUE 149.53
- 52 Week Low
- GLU $11.61
- CUE $0.45
- 52 Week High
- GLU $15.40
- CUE $2.37
- Technical
- Relative Strength Index (RSI)
- GLU 60.55
- CUE 48.32
- Support Level
- GLU $15.64
- CUE $1.22
- Resistance Level
- GLU $16.28
- CUE $1.54
- Average True Range (ATR)
- GLU 0.33
- CUE 0.11
- MACD
- GLU 0.07
- CUE -0.01
- Stochastic Oscillator
- GLU 77.23
- CUE 35.29
About GLU Gabelli Global Utility of Beneficial Ownership
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.